Laure DUTRIEUX, Sara OVEJERO, Antoine GUILLEMIN, Miss Leriem ZELLAGUI, Elke De BRUYNE, Catharina MUYLAERT, Lien VAN HEMELRIJCK, Yea-Lih LIN, Elle LOUGHRAN, Armelle CHOQUET, Talha MAGAT, Soumya BOUCHOUIKA, Caroline BRET, Guilhem REQUIRAND, Nicolas ROBERT, Laure VINCENT, Guillaume CARTRON, Charles HERBAUX, Raphaël RODRIGUEZ, Michel COGNE, Eric RIVALS, Jean-Christophe ANDRAU, Alexandre DAVID, Philippe PASERO, and Jérôme MOREAUX
Tubulin detyrosination shapes Leishmania cytoskeletal architecture and virulence.
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.
Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.
Tomowiak C, Poulain S, Nudel M, Feugier P, Herbaux C, Mahé B, Morel P, Aurran T, Tournilhac O, Leprêtre S, Assaad S, Villemagne B, Casasnovas O, Lhermitte A, Roos-Weil D, Torregrosa-Diaz J, Chevret S, Leblond V, on the behalf of the FILO group
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.
Arribas AJ, Napoli S, Gaudio E, Herbaux C, Cannas E, Tarantelli C, Bordone-Pittau R, Cascione L, Munz N, Aresu L, Sgrignani J, Rinaldi A, Kwee I, Rossi D, Cavalli A, Zucca E, Stussi G, Stathis A, Sloss C, Davids MS, Bertoni F
Rojas-Ríos P, Chartier A, Enjolras C, Cremaschi J, Garret C, Boughlita A, Ramat A, Simonelig M
Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials.
Lenz G, Tilly H, Ziepert M, Altmann B, Herbaux C, Frontzek F, Nickelsen M, Lee C, Hirata J, Sahin D, Chohan S, Batlevi CL, Yan M, Morschhauser F, Schmitz N
CD38, CD39, and BCL2 differentiate disseminated forms of high-grade B-cell lymphomas in biological fluids from Burkitt lymphoma and diffuse large B-cell lymphoma.
